GlycoMimetics Forges Ahead With Uproleselan In AML After Phase III Failure

The company said an NCI trial and a China study remain ongoing despite a Phase III study in relapsed/refractory disease failing, with an unusually long OS result in the control arm.

• Source: Shutterstock

GlycoMimetics, Inc. is hoping that mining the data from its failed Phase III pivotal trial of uproleselan in acute myeloid leukemia (AML) can potentially yield some evidence of benefit in subgroup populations. Meanwhile, additional studies of the drug in other settings are ongoing.

The company said 6 May that the 388-patient Phase III pivotal study had not shown a statistically significant improvement in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

 

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By 

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By 

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

More from R&D